z-logo
Premium
BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B‐cell lymphoma
Author(s) -
Hoeller Sylvia,
Zihler Deborah,
Zlobec Inti,
Obermann Ellen C,
Pileri Stefano A,
Dirnhofer Stephan,
Tzankov Alexandar
Publication year - 2010
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2009.03462.x
Subject(s) - cd30 , cd15 , lymphoma , pathology , tissue microarray , cyclin d1 , immunohistochemistry , medicine , cd20 , cancer research , biology , cd34 , cell cycle , cancer , stem cell , genetics
Hoeller S, Zihler D, Zlobec I, Obermann EC, Pileri SA, Dirnhofer S & Tzankov A
(2010) Histopathology 56, 217–228 BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B‐cell lymphomaAims:  To clarify which immunohistochemical markers could be helpful in distinguishing between classical Hodgkin’s lymphoma (cHL) and primary mediastinal B‐cell lymphoma (PMBCL) to more narrowly define ‘B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and cHL’. Methods and results:  Two hundred and 83 cHLs and 51 PMBCLs were analysed on validated tissue microarray platforms with antibodies to BOB.1, CD15, CD20, CD23, CD30, CD79a, cyclin E, LMP‐1, MUM1p, p63 and Oct2. The marker cut‐off scores were calculated using receiver–operating characteristic curves. Markers with the highest positive predictive value for cHL were: CD15, cyclin E, LMP‐1 (all 100%), MUM1p (93%) and CD30 (83%). High sensitivity was achieved only by CD30 (92%) and cyclin E (79%). Nineteen percent of PMBCLs were also positive for CD30, which led to a lower specificity of CD30 as regards cHL (81%) compared with cyclin E (100%). The antibodies with the highest positive predictive value for PMBCL were: CD23 (98%), p63 (96%), BOB.1 (94%) and CD79a (90%), with high sensitivity for BOB.1 (100%), CD79a (89%) and p63 (82%). Conclusions:  The use of at least three of the most accurate immunohistochemical markers, cyclin E, CD79a and BOB.1, may be helpful in the differential diagnosis of cHL and PMBCL.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here